BC World Pharm Announced on 1 September 2026 That It Was Selected With Qunova Computing to Target Pan-Beta-Lactamase and Penicillin-Binding Proteins
Quentir Medicine Monitor
Evidence-based insights for quantum medicine. Published by Quentir Systems LLC · September 3, 2026.
An infectious disease physician facing a resistant Gram-negative infection chooses among a small number of remaining drugs. The reason the number is small is chemical. Bacteria carrying beta-lactamase enzymes cut the beta-lactam ring before the antibiotic reaches the protein it was meant to block. One clinical strategy has been to pair the antibiotic with an inhibitor that protects it, and that strategy keeps running out because the approved inhibitors do not cover every enzyme.
On 1 September 2026 BC World Pharm announced that it had been selected as lead research institution for a Korean government project intending to find compounds that hit pan-beta-lactamase and penicillin-binding proteins at the same time, with Qunova Computing, a quantum computer based computational chemistry company, as co-research institution. The cited announcements state no budget or project term.
What BC World Pharm Announced on 1 September 2026, and Under Which Instrument
The project sits in the Ministry of SMEs and Startups' SME Technology Innovation Development Project, in a track for promising SME technologies aimed at AI-driven discovery of drug candidates. Finance Scope carried the company's announcement on the day it was made, labeled as a press release, and Edaily reported the same content. The ministry's own award record was not retrieved for this reading: the Ministry of Science and ICT website returned a maintenance notice during this work, and no ministry page for this award was reachable, so everything here rests on the company announcement as carried by those two outlets.
BC World Pharm leads; Qunova Computing joins as the computational partner. The two say they will build a drug design workflow using AI and quantum mechanics based multi-target design, with the stated intention of carrying a lead compound into preclinical development as a new pipeline asset. A company representative framed it as combining BC World Pharm's development capability with Qunova Computing's precision computational design. That is the whole of the public claim. Neither report carries a compound, an assay result, a comparator or a timeline.
Why Aiming at Both Enzyme Families at Once Is a Difficult Design Problem
The two targets do different jobs, and one molecule that engages both is a demanding brief.
Penicillin-binding proteins are what every beta-lactam antibiotic is aimed at. They build the bacterial cell wall, and a drug that occupies them stops the wall from being assembled. Beta-lactamases are the defense the bacterium evolved against exactly that: enzymes that hydrolyze the drug's four-membered ring before it arrives. They are grouped by the Ambler classification into four classes, of which A, C and D use a serine residue to do the cutting, and class B uses zinc. Class B enzymes are the metallo-beta-lactamases, and they are the reason the field keeps building new inhibitors.
The gap is documented in the inhibitor literature. Hamrick and colleagues, writing in Antimicrobial Agents and Chemotherapy in 2020, place clavulanic acid and tazobactam mainly against class A, describe avibactam as reaching classes A, C and D, and state that among the inhibitors approved at that time none covered both the clinically important serine enzymes such as KPC and OXA-48 and the clinically important metallo-beta-lactamases. Their own subject, taniborbactam, is presented there as the first inhibitor with direct activity across all four Ambler classes, with reported inhibition constants including 0.081 micromolar against NDM-1 and 0.019 micromolar against VIM-2. That breadth has a documented exception: against IMP-1 the reported constant was above 30 micromolar, taniborbactam did not potentiate cefepime in the IMP-1 overproducing strain, and IMP-producing strains were excluded from the clinical isolate testing. The pathogens where these limits bite are set out in the World Health Organization's bacterial priority pathogens list of 17 May 2024, which covers 24 pathogens across 15 families and places carbapenem-resistant and third-generation cephalosporin-resistant Enterobacterales in its critical group, on grounds of burden, transmissibility, treatability and the state of the pipeline.
Quantum pillar: computing. Technology readiness: TRL 2 of 9. Rung two means a technology concept or application has been formulated, and that is this Monitor's assessment of what the public evidence shows: an announced project describing a design workflow, with no project-specific compound, assay or comparator disclosed in the cited reports, and with the computational method the project will use not identified in them.
What BC World Pharm and Qunova Computing describe is a compound that inhibits the destroying enzymes broadly and binds the target protein, in one chemical structure. Both protein families bind beta-lactams, which is what makes dual activity conceivable as a design goal. The announcements do not describe the chemical approach, so how the two binding requirements would be reconciled in one molecule is not established by anything in the public record.
What Qunova Computing Brings, and What the Announcement Does Not Say About It
Qunova Computing was founded in 2021 by KAIST professor June-Koo Kevin Rhee and is based in Daejeon. Its algorithm HI-VQE is a hybrid quantum and classical method for computational chemistry, which Quantum Computing Report covered when the company closed a Series A of KRW 13.5 billion, around USD 10 million, in August 2025. The company reports demonstrations on quantum chemistry problems at qubit counts up to 68, hardware agnostic across several machines, and a listing in IBM's Qiskit functions catalog. Those performance figures are company-reported.
The announcement of this project does not identify HI-VQE, a backend, a circuit or any hardware-specific result. It describes AI and quantum mechanics based multi-target drug design, and quantum mechanics based design is also standard vocabulary for classical quantum chemistry, the density functional and coupled cluster methods that have run on ordinary computers for decades. That ambiguity limits what can be inferred about quantum-hardware involvement here. This Monitor drew the same distinction when QC Ware and IonQ mapped four orbitals of a cytochrome P450nor active site onto eight qubits on 1 September, where the hardware involvement was specified precisely.
Two Korean Announcements Four Days Apart, Under Two Different Ministry Instruments
This is the second reported Korean selection in a week pairing a pharmaceutical company with a computational drug-design company, and the two sit under different programs, which is worth stating plainly because they are easy to read as one.
On 28 August, The BioNews reported that D&D Pharmatech had been named lead institution under the ministry's Pharma-Bio Venture Collaboration Technology Development Project, in its AI candidate discovery track, working with Quantum Intelligence. That project targets an oral alpha-4-beta-7 integrin candidate for inflammatory bowel disease, combining Quantum Intelligence's design platform with D&D's ORALINK oral peptide delivery technology, at KRW 1.358 billion over 24 months from July 2026 to June 2028, with the stated aim of an oral candidate that addresses the convenience and cost limitations of injected antibody therapy. The BC World Pharm announcement came four days later, under the SME Technology Innovation Development Project, a separate instrument, with no disclosed budget or term.
Two reported selections under two ministry programs do not establish a national strategy, and this Monitor does not read one into them. What they do show is program structure: both tracks are written to pair a pharmaceutical developer with a computational-design partner, and both announcements landed inside one week. Both projects are at candidate-discovery stage and could produce compounds for later preclinical testing, whose merits would then have to be judged on assay data like any other.
What Would Count as Progress Here
The available evidence supports a narrow conclusion. A selection has been announced for a chemistry problem that is hard for reasons independent of the computational method, and multi-target inhibitor design has been attempted with classical methods for years. Compute on its own does not establish biological activity.
Progress would be visible in a specific sequence. First, project-specific structures or a compound series with measured inhibition constants against representative enzymes from each Ambler class, which is the format Hamrick and colleagues used and the format a reviewer can check. Then minimum inhibitory concentrations against clinical isolates carrying characterized resistance mechanisms, since enzyme inhibition on its own does not establish that a compound reaches its target inside a living bacterium. And alongside both, an account of which calculations ran on which hardware, so that the quantum contribution can be separated from the AI contribution and from ordinary medicinal chemistry.
Until a compound series with assay data is disclosed, this is an announced project with a defensible target selection and an undisclosed budget, in a therapeutic area where the clinical need is documented by the World Health Organization.
Sources
Primary source: BC World Pharm's own announcement of 1 September 2026, which is the primary source available for this reading, carried as a press release by Finance Scope, "비씨월드제약, 중기부 AI 신약개발 R&D 주관기관 선정," and reported the same day by Edaily, for the company's selection as lead research institution under the Ministry of SMEs and Startups' SME Technology Innovation Development Project, the promising-SME-technology AI candidate discovery track, Qunova Computing's participation as co-research institution, the pan-beta-lactamase and penicillin-binding protein targets, the intention to carry a lead compound to preclinical development, and the company statement; neither report states a budget or a project term, and the Ministry of Science and ICT site returned a maintenance notice during this reading, so no ministry award record was retrieved. The Ambler classification, the placement of clavulanic acid and tazobactam, avibactam's class coverage, the statement that no inhibitor approved as of 2020 covered both the clinically important serine and metallo enzymes, taniborbactam's activity across all four classes with the NDM-1 and VIM-2 constants, and the IMP-1 exception with its constant above 30 micromolar and absent potentiation of cefepime come from Hamrick and colleagues in Antimicrobial Agents and Chemotherapy, 2020. The pathogen counts, the critical group and the grounds for classification come from the World Health Organization's bacterial priority pathogens list of 17 May 2024. Qunova Computing's founding in 2021 by KAIST professor June-Koo Kevin Rhee comes from KAIST's own page; its HI-VQE algorithm, the Series A of KRW 13.5 billion in August 2025, the company-reported qubit counts and the Qiskit catalog listing come from Quantum Computing Report. The D&D Pharmatech and Quantum Intelligence project, its instrument, budget, term and stated aim comes from The BioNews of 28 August 2026. The judgments are this Monitor's own: that the two announcements run under different ministry instruments and do not by themselves establish a national pattern, that quantum mechanics based design does not establish quantum hardware involvement, and that inhibition constants by Ambler class followed by minimum inhibitory concentrations against characterized isolates are what would turn this plan into evidence.